抗结核药盐酸莫西沙星缓控释制剂研究进展

Research advance in antituberculosis drug Moxifloxacin hydrochloride controlled-release preparations

莫西沙星(moxifloxacin)作为第四代喹诺酮类超广谱抗菌药,其最低抑菌浓度低、抗耐药特性较强,在抗结核药物中具优势和潜力。耐药结核菌群不断出现、一线药物临床疗效下降、患者顺应性差等使结核病临床治愈率低。为此,开发适合肺部介入给药的莫西沙星缓释制剂,以减少给药次数、增加患者顺应性,具有理论意义与临床价值。综述近年来出现的脂质体、微球、纳米粒子等莫西沙星缓控释制剂的国内外研究进展,为新药研发提供依据。

Moxifloxacin（MXF） is a novel fourth generation fluoroquinolone with a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria,anaerobes,and atypical organisms,the lower MIC value and high antibacterial effects make it a suitable antibiotic for treating various infectious diseases.The drug-resistant strains,the clinical efficacy decline of the first-line drugs including isoniazid and rifampicin equality,and the decreasing of resistance of patients push the therapy of the infection caused by drug-resistant strains in an embarrassing place.Therefore,it is imperative to research the MXF controlled-release preparation for pulmonary intervention therapy to decrease the dosage and improve the patient＇s compliance.The paper summarizes the study progress on MXF controlled-release preparation such as liposome,microsphere,and nanoparticle,both in China and abroad.